文献速递精神分裂症与精神病性障碍

选择性ROCK2抑制剂KD025在精神分裂症小鼠模型中的抗精神病样作用

Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia.
PubMed 文献 · Mol Psychiatry · 2026-04-01

该研究在Arhgap10基因突变小鼠及甲基苯丙胺、MK-801药理学模型中评估选择性ROCK2抑制剂KD025。KD025口服可抑制ROCK底物MYPT1磷酸化升高、改善内侧前额叶皮层锥体神经元树突棘密度下降,并减轻视觉辨别、新物体识别及高活动性损害。有效剂量下未影响收缩压,未诱发锥体外系症状、高催乳素血症或高血糖。

要点

  • KD025改善Arhgap10突变小鼠的内侧前额叶皮层树突棘密度下降及ROCK底物磷酸化异常升高。
  • KD025减轻甲基苯丙胺和MK-801诱导的视觉辨别、新物体识别及高活动性损害。
  • 有效剂量下KD025未影响收缩压,未诱发锥体外系症状、高催乳素血症或高血糖。

核心结论

  • 选择性ROCK2抑制剂KD025在遗传和药理学精神分裂症小鼠模型中表现出抗精神病样作用,且不良反应谱较好。

研究设计与样本

  • 研究采用遗传模型Arhgap10 S490P/NHEJ小鼠和药理学模型(甲基苯丙胺、MK-801处理),评估选择性ROCK2抑制剂KD025的抗精神病样作用及不良反应。

主要发现

  • KD025口服抑制ROCK底物MYPT1磷酸化水平异常升高,并改善Arhgap10 S490P/NHEJ小鼠内侧前额叶皮层2/3层锥体神经元树突棘密度下降。
  • KD025减轻甲基苯丙胺诱导的Arhgap10 S490P/NHEJ和野生型小鼠视觉辨别损害。
  • KD025减轻MK-801诱导的视觉辨别、新物体识别损害及高活动性。
  • 有效剂量下KD025未影响野生型小鼠收缩压,未诱发锥体外系症状、高催乳素血症或高血糖。

临床怎么用

  • 提示选择性ROCK2抑制可能作为精神分裂症治疗候选策略,且因避开ROCK1而可能减少部分不良反应。

局限性

  • 证据仅来自小鼠模型,尚未在人体中验证疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Copy number variations in the ARHGAP10 gene encoding Rho GTPase-activating protein 10 are significantly associated with schizophrenia. ARHGAP10 negatively regulates RhoA/Rho-kinase (ROCK) signaling. We previously demonstrated that fasudil, a non-selective ROCK inhibitor, exhibited antipsychotic-like effects in several mouse models of schizophrenia. ROCK has two subtypes, ROCK1 and ROCK2. ROCK1 is mainly expressed in the thymus and blood, while ROCK2 is predominantly expressed in the brain. Therefore, it is expected that like fasudil, selective ROCK2 inhibitors will exhibit antipsychotic-like effects, accompanied by a lower incidence of adverse effects due to ROCK1 inhibition. Here, we used genetic and pharmacological models of schizophrenia to investigate whether the selective ROCK2 inhibitor KD025 would show antipsychotic-like effects with a favorable adverse effect profile. Oral administration of KD025 suppressed the abnormal increase in the phosphorylation level of myosin phosphatase-targeting subunit 1, a substrate of ROCK, and ameliorated the decreased spine density of layer 2/3 pyramidal neurons in the medial prefrontal cortex of Arhgap10 S490P/NHEJ mice. Furthermore, KD025 mitigated the methamphetamine-induced impairment of visual discrimination (VD) in Arhgap10 S490P/NHEJ and wild-type mice. KD025 also reduced MK-801-induced impairments of VD, novel object recognition, and hyperlocomotion. Regarding side effects that are commonly seen with typical antipsychotics, KD025 did not affect systolic blood pressure and did not induce extrapyramidal symptoms, hyperprolactinemia, or hyperglycemia at the effective dosage in naïve wild-type mice. Taken together, KD025 shows antipsychotic-like effects with a favorable adverse effect profile in genetic and pharmacological mouse models of schizophrenia.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tanaka R, Liao J, Liu Y, et al. Antipsychotic-like effects of the selective Rho-kinase 2 inhibitor KD025 in genetic and pharmacological mouse models of schizophrenia. Mol Psychiatry. 2026. PMID: 41922796. doi:10.1038/s41380-026-03567-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。